VERU - Veru granted expedited Australian regulatory pathway for COVID-19 treatment
- The Australian Therapeutic Goods Administration (TGA) had determined that Veru's ( NASDAQ: VERU ) sabizabulin treatment in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome qualifies for an expedited, provisional registration regulatory pathway.
- ( VERU ) stock rose ~4% premarket.
- if the application is authorized, it would allow the drug to be prescribed in Australia earlier than the standard registration process.
- Veru’s regulatory agent in Australia is Adjutor Healthcare.
For further details see:
Veru granted expedited Australian regulatory pathway for COVID-19 treatment